Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings

Míreanna comhchosúla

• 46 Efficacy of atezolizumab and docetaxel in patients with HER2-positive non-small cell lung cancer: a pooled post hoc of the OAK and POPLAR trials
  de réir: Jian-Guo Zhou, et al.
  Foilsithe / Cruthaithe: (2023-11-01)
• Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy
  de réir: Jie Yang, et al.
  Foilsithe / Cruthaithe: (2024-07-01)
• Feasibility and Safety of Anlotinib Plus Docetaxel versus Docetaxel Monotherapy in Patients with Previously Immunotherapy-Treated NSCLC: A Retrospective Exploratory Study
  de réir: Li DW, et al.
  Foilsithe / Cruthaithe: (2025-04-01)
• Quality-of-life scale machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer
  de réir: Juanyan Shen, et al.
  Foilsithe / Cruthaithe: (2025-07-01)
• Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells
  de réir: Fridolin Grottker, et al.
  Foilsithe / Cruthaithe: (2023-11-01)